BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $14.67 Average Target Price from Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have earned a consensus recommendation of “Moderate Buy” from the six analysts that are covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $14.67.

A number of equities analysts recently issued reports on BCRX shares. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and issued a $14.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. StockNews.com raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. Finally, Barclays upped their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th.

BioCryst Pharmaceuticals Price Performance

BCRX opened at $8.19 on Friday. The firm’s fifty day moving average price is $7.75 and its 200 day moving average price is $7.07. The stock has a market capitalization of $1.70 billion, a PE ratio of -13.43 and a beta of 1.89. BioCryst Pharmaceuticals has a 12-month low of $4.03 and a 12-month high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.07). The business had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. During the same quarter in the previous year, the business posted ($0.19) earnings per share. The company’s quarterly revenue was up 35.1% compared to the same quarter last year. On average, equities research analysts forecast that BioCryst Pharmaceuticals will post -0.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Intech Investment Management LLC acquired a new position in shares of BioCryst Pharmaceuticals during the third quarter worth approximately $412,000. Counterweight Ventures LLC grew its stake in shares of BioCryst Pharmaceuticals by 591.7% in the third quarter. Counterweight Ventures LLC now owns 93,384 shares of the biotechnology company’s stock worth $710,000 after acquiring an additional 79,884 shares during the last quarter. Aigen Investment Management LP increased its position in BioCryst Pharmaceuticals by 75.0% during the third quarter. Aigen Investment Management LP now owns 28,661 shares of the biotechnology company’s stock worth $218,000 after acquiring an additional 12,280 shares during the period. Principal Financial Group Inc. raised its stake in BioCryst Pharmaceuticals by 1,058.1% during the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock valued at $3,127,000 after purchasing an additional 375,890 shares during the last quarter. Finally, Rice Hall James & Associates LLC boosted its holdings in BioCryst Pharmaceuticals by 4.0% in the 3rd quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock valued at $16,444,000 after purchasing an additional 84,102 shares during the period. Institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.